Clinical trial • Phase I/II • Oncology
STAR0602 for Unresectable, Locally Advanced, or Metastatic Solid Tumors
Phase I/II trial of STAR0602 for Unresectable, Locally Advanced, or Metastatic Solid Tumors. 225 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Unresectable, Locally Advanced, or Metastatic Solid Tumors
- Trial Stage
- Phase I/II
Key dates
- Initial CTIS Submission Date
- 19-04-2024
- First CTIS Authorization Date
- 08-07-2024
Trial design
Phase I/II trial across 12 sites in Spain, France.
- Target Sample Size
- 225
Recruitment
- Planned Sample Size
- 225
- Recruitment Window Months
- 23
Geography
- Total Number Of Sites
- 12
- Total Number Of Participants
- 73
Spain
- Earliest CTIS Part Ii Submission Date
- 28-06-2024
- Latest Decision Or Authorization Date
- 15-04-2025
- Processing Time Days
- 291
- Number Of Sites
- 7
- Number Of Participants
- 23
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncology
- Contact Person Name
- Eduardo Castañon
- Contact Person Email
- ecastanon@unav.es
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Oncology
- Contact Person Name
- Susana Roselló
- Contact Person Email
- srosello@incliva.es
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- NEXT Madrid Phase I trials
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Contact Person Name
- Elena Garralda
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncology
- Contact Person Name
- Ignacio Matos
- Contact Person Email
- imatos@unav.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- START Madrid
- Contact Person Name
- Manuel Pedregal
- Contact Person Email
- manuel.pedregal@startmadrid.com
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Medical Oncology
- Contact Person Name
- Omar Saavedra
- Contact Person Email
- osaavedra@nextoncology.eu
France
- Earliest CTIS Part Ii Submission Date
- 17-05-2024
- Latest Decision Or Authorization Date
- 04-09-2025
- Processing Time Days
- 475
- Number Of Sites
- 5
- Number Of Participants
- 50
Sites
- Site Name
- Institut Bergonié
- Department Name
- Oncologie Médical
- Contact Person Name
- Antoine Italiano
- Contact Person Email
- a.italiano@bordeaux.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- DITEP
- Contact Person Name
- Aurélien Marabelle
- Contact Person Email
- aurelien.marabelle@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Oncologie Médicale
- Contact Person Name
- Philippe Cassier
- Contact Person Email
- philippe.cassier@lyon.unicancer.fr
- Site Name
- Oncopole Claudius Regaud
- Department Name
- Oncologie Médicale
- Contact Person Name
- Carlos Gomez Roca
- Contact Person Email
- gomez-roca.carlos@iuct-oncopole.fr
- Site Name
- Institut Curie
- Department Name
- Oncologie Médicale
- Contact Person Name
- Clara Vacheret
- Contact Person Email
- clara.vacheret@curie.fr
Sponsor
Primary sponsor
- Full Name
- Marengo Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- STAR0602
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)